Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

The neuro-protective effect of antenatal magnesium sulfate on very preterm infants has been
demonstrated in good-quality randomised controlled trials and meta-analyses. Magnesium …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

Cerebral palsy (CP) remains the most significant neurological disorder associated with
preterm birth. It disrupts quality of life and places huge cost burdens on society. Antenatal …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Background Magnesium sulphate is a common therapy in perinatal care. Its benefits when
given to women at risk of preterm birth for fetal neuroprotection (prevention of cerebral palsy …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …